



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

EXAMINER
----------

ART UNIT	PAPER NUMBER
----------	--------------

5

DATE MAILED:

This is a communication from the examiner in charge of your application  
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

Responsive to communication(s) filed on 6/2/95 + 9/11/95

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 0 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 13-18 is/are pending in the application.

Of the above, claim(s) is/are withdrawn from consideration.

Claim(s) is/are allowed.

Claim(s) is/are rejected.

Claim(s) is/are objected to.

Claims 13-18 are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on is/are objected to by the Examiner.

The proposed drawing correction, filed on is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d)

All Some\* None of the CERTIFIED copies of the priority documents have been received

received in Application No. (Series Code Serial Number)

received in this national stage application from the International Bureau (PCT Rule 17.2(a))

\*Certified copies not received


Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e)

Attachment(s)

By way of preliminary amendment, claims 1-12, 19 and 20 have been cancelled. Claims 13-18 are pending.

♦ ♦

This application contains claims directed to the compounds encompassed by claim 13. Applicant is required under 35 U.S.C. §121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Claim 13 is drawn to peptides of the following formula, wherein A and A' are amino acids, and "m" is an integer between 1 and 10:



For any A and A', a change in the value of "m" will lead to a patentably distinct compound. A change in "A" from, e.g., lysine to glutamic acid or from tryptophan to valine would lead to patentably distinct compounds. However, a change from leucine to valine or from phenylalanine to tyrosine would lead compounds which are "obvious variants" (barring a showing of significant change in biological properties).

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a generic claim is allowable or that all claims are generic is

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP 309.02(a).

Should applicant traverse on the ground that the species are not patentable distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. §103 of the other invention.

Applicant is advised that for the response to this requirement to be complete, an election of the invention to be examined must be indicated, even if the requirement is traversed (37 C.F.R. 1.143).

A telephone call was made to Paul Clark on 5/20/96 to request an oral election to the above restriction requirement, but did not result in an election being made.

•

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is (703) 308-3213.

An inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 303-0196.



DAVID LUKTON  
PATENT EXAMINER  
GROUP 1800